Boehringer Ingelheim buys Pharmaxis NASH candidate
This article was originally published in Scrip
Boehringer Ingelheim is to pay €27.5m up front plus upwards of €500m in milestones to acquire a Phase I candidate that has shown preclinical promise in non-alcoholic steatohepatitis (NASH) from Pharmaxis. The German company is exercising an option that it already held to acquire the investigational drug PXS4728A, a semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor that is designed to block leucocyte adhesion and tissue infiltration in inflammatory processes.
You may also be interested in...
With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.
There is growing impetus at the highest EU levels towards ensuring the IVD Regulation is implemented as quickly and effectively as possible. Discussion at the Council of the EU have now added to this drive.
Trade group offers timeline for shift in FDA thinking about the amino acid commonly used in supplements in complaint seeking to block agency from preventing sales of NAC-containing supplements. Complaint also attests that, unlike its current stance, FDA in 1993 acknowledged NAC is lawful for use as a dietary ingredient.